Inactive Instrument
DIAL BIORFD Stock Nasdaq Stockholm
Stocks
DIABIO BTA
SE0019173832
Biotechnology & Medical Research
| 1 day | +2.99% |
| Manager | Title | Age | Since |
|---|---|---|---|
Karin Wehlin
CEO | Chief Executive Officer | - | 23/11/2023 |
Fata Mrsic
DFI | Director of Finance/CFO | - | 14/06/2024 |
Emelie Danefur
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Karin Wehlin
BRD | Director/Board Member | - | 01/05/2023 |
| Chairman | 70 | 01/01/2021 | |
| Director/Board Member | 41 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.99% | +15.00% | - | - | 705K | |
| -0.62% | -1.87% | +46.31% | +56.99% | 64.38B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.16B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.16B | |
| -2.81% | -4.31% | +23.50% | +50.90% | 45.33B | |
| -0.33% | -1.93% | +20.15% | +98.45% | 42.25B | |
| +0.55% | +2.31% | +224.97% | +942.56% | 40.78B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 33.8B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.25B | |
| +0.89% | +20.55% | -42.03% | +373.03% | 24.37B | |
| Average | +0.60% | +6.96% | +47.86% | +206.32% | 43.72B | |
| Weighted average by Cap. | +0.16% | +4.84% | +48.31% | +185.47% |
Employees
4
